Abstract
Siglec15 (S15) is a glycan-recognition protein that has emerged as a significant immune checkpoint, often highly expressed on tumor-associated macrophages (TAMs) and various tumor cells. While S15 is known to inhibit T cell activity, the precise biological mechanisms underlying this suppression have remained elusive. This study investigates the impact of S15 on myeloid cell populations and describes the development of ES012, a humanized monoclonal antibody designed to reverse S15-mediated immunosuppression. Our findings reveal that S15 does not directly target T cells but instead induces apoptosis in monocytes and inhibits their activation. ES012 effectively blocks S15 interactions with multiple ligands, rescues monocyte function, and demonstrates potent anti-tumor activity in preclinical models, including a 100% complete response rate in syngeneic mouse studies.
Introduction
In the evolving landscape of cancer immunotherapy, identifying novel checkpoints is critical for patients who do not respond to traditional PD-1/PD-L1 inhibitors. Siglec15 (S15), a member of the Siglec family that preferentially recognizes the Neu5Aca2–6GalNAca– structure, has become a target of intense interest. Although S15 is known to be induced by M-CSF and expressed on TAMs to suppress the immune microenvironment, the specific cellular pathways involved in this suppression were previously unclear. This research sought to clarify whether S15 acts directly on T cells or through intermediary myeloid cells, and subsequently to develop a therapeutic antibody to counteract these effects.
Uncovering the Mechanism: The Indirect Hit
A primary focus of this study was characterizing S15 expression and binding across immune cell subsets. Profiling of healthy donor peripheral blood mononuclear cells (PBMCs) revealed that S15 is expressed on monocytes, M2 macrophages, and dendritic cells, but notably absent from M1 macrophages. Functional assays using S15-Fc fusion proteins demonstrated a dose-dependent inhibition of T cell proliferation when stimulated by OKT3.
Crucially, this inhibitory effect vanished when T cells were stimulated by methods that bypass monocyte involvement, such as PMA/ionomycin or CD3/CD28 beads. This suggests that S15 does not directly suppress T cell activity. Instead, the study found that S15 induces apoptosis in monocyte subsets and down-regulates essential activation markers, including CD86, HLA-DR, and CD14. By eliminating or deactivating these vital antigen-presenting cells, S15 effectively starves T cells of the signals required for activation.
Development and Characterization of ES012
To address this immunosuppressive mechanism, researchers screened and characterized a series of anti-Siglec15 antibodies. The lead candidate, ES012, was selected based on its superior antigen binding and ligand-blocking capabilities. Epitope mapping via hydrogen deuterium exchange mass spectrometry (HDX-MS) and Bio-layer interferometry (BLI) confirmed that ES012 targets a specific region of S15, allowing it to block interactions with multiple ligands, including SiaTn and LRRC4C.
In vitro testing demonstrated that ES012 could dose-dependently:
- Rescue monocytes from S15-mediated apoptosis.
- Reverse the down-regulation of monocyte activation markers.
- Restore T cell proliferation in PBMC cultures.
Preclinical Efficacy and Safety
The therapeutic potential of ES012 was evaluated in vivo using human S15 knock-in B6/C57 mice bearing MC38 tumors. The results were striking: at a dose of 5 mg/kg, ES012 achieved a 100% complete response (CR) rate, with tumors being entirely cleared in the syngeneic model.
Furthermore, preclinical assessment included pharmacokinetics (PK) and acute toxicity studies in cynomolgus monkeys. ES012 exhibited a favorable PK profile and no significant safety concerns in these non-human primate models, supporting its viability for clinical progression.
Conclusion
This study redefines our understanding of Siglec15 biology, shifting the focus from direct T cell inhibition to a myeloid-driven mechanism of immunosuppression. By inducing monocyte apoptosis and preventing their activation, S15 creates a protective shield for tumors. The development of ES012 provides a potent tool to dismantle this shield. With its ability to rescue myeloid cell function and its exceptional anti-tumor efficacy in preclinical models, ES012 represents a promising new candidate for cancer immunotherapy, particularly for patients whose tumors exploit the S15 pathway to evade the immune system.
Summary updated